id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-251961-g0n85kxz	Li, Guoming	Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial	2020-11-02		.txt	text/plain	3408	190	53	CONCLUSIONS: In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. According to the "China's Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Seventh Edition) ", COVID-19 patients are usually categorized into mild, moderate, severe, and critical based on their symptoms. Initially, this trial was an open-label randomized parallel-group controlled trial intended to compare the efficacy and safety of AP tablets in comparison with hydroxychloroquine to treat patients with mild to moderate COVID-19. And the rate of patients to undetected SARS-CoV-2 by RT-PCR at day 7, 10, 14, 21, and 28 during drug administration, the CT images results within ten days, the abnormal laboratory index and adverse events would be compared between the two treatments.	./cache/cord-251961-g0n85kxz.txt	./txt/cord-251961-g0n85kxz.txt